



## Phio Pharmaceuticals to Highlight Self-delivering RNAi Technology at SITC 2019

October 29, 2019

MARLBOROUGH, Mass., Oct. 29, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that several posters featuring INTASYL™ will be presented at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting, held November 6-10 at the Gaylord National Hotel and Convention Center in National Harbor, MD. Three posters, reflecting internal work and work in collaboration with Iovance Biotherapeutics, Inc. and the Karolinska Institutet, will be highlighting Phio's proprietary INTASYL™ technology for "weaponizing" T cells against cancer.

Logo - [https://mma.prnewswire.com/media/786567/Phio\\_Pharmaceuticals\\_Logo.jpg](https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg)

### Presentation Details:

Poster: P149

Date: Friday November 8, 2019

Title: Silencing PD-1 using self-delivering RNAi PH-762 to improve Iovance TIL effector function using Gen 2 manufacturing method

Category: Cellular Therapies

Authors: Inbar Azoulay-Alfaguter, PhD; Michelle R. Abelson, PhD; Krit Ritthipichai, DVM, PhD; Kenneth D'Arigo; Florangel Hilton; Marcus Machin, BS; Dingxue Yan; James Cardia; Maria Fardis, PhD, MBA; Cecile Chartier

Poster: P222

Date: Saturday November 9, 2019

Title: Modulating BRD4 in T cells using self-delivery RNAi to improve adoptive cell therapy of cancer

Category: Cellular Therapies

Authors: Jeroen Melief, PhD; Laura L. Van Leeuwe Kirsch, BSc; Esmeralda Hemme; John A. Barrett, PhD; Simon P. Fricker, PhD; Gerrit Dispersyn, PhD; Rolf Kiessling, MD, PhD

Poster: P760

Date: Saturday November 9, 2019

Title: Local modulation of T cell PD-1 using self-delivering RNAi as a potential immunotherapeutic

Category: Novel Single-Agent Immunotherapies

Authors: John A. Barrett, PhD; James Cardia; Melissa Maxwell; Mani D. Kadiyala, M.S.; Dingxue Yan, PhD; Winnie Tam; Simon P. Fricker, PhD; Gerrit Dispersyn, PhD

### About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through our proprietary INTASYL™ platform with utility in immune cells and/or the tumor micro-environment. Our goal is to develop powerful INTASYL™ therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, [www.phio-pharma.com](http://www.phio-pharma.com).

### Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the safety and efficacy of our product candidates, future success of our clinical trials and scientific studies, expected duration of available cash runway, our ability to enter into strategic partnerships and the future success of these strategic partnerships, the availability of funds and resources to pursue our research and development projects and general economic conditions. Our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q include detailed risks under the caption "Risk Factors" that may affect our business, results of operations and financial condition. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

### Contact

Phio Pharmaceuticals Corp.

[ir@phio-pharma.com](mailto:ir@phio-pharma.com)

### Investor Contact

Ashley R. Robinson

LifeSci Advisors  
[arr@lifesciadvisors.com](mailto:arr@lifesciadvisors.com)

 View original content: <http://www.prnewswire.com/news-releases/phio-pharmaceuticals-to-highlight-self-delivering-rnai-technology-at-sitc-2019-300946665.html>

SOURCE Phio Pharmaceuticals Corp.